Research on Mechanism of FGFR1 Inhibitor BAY1163877 against Proliferation of Breast Cancer Cells

Author:

Cui Yingnan,Zhang Li,Xing Jin,Yang Zhaoying

Abstract

Abstract To investigate the effect and mechanism of fibroblast growth factor receptor 1 (FGFR1) inhibitor BAY1163877 on proliferation and apoptosis of breast cancer cells. The expression of FGFR1 in human breast cell lines was detected by qRT-PCR and western blot. IC50 of BAY1163877 and cell viability were measured by CCK-8 method. Cell proliferation was observed by colony assay. Cell apoptosis after treatment of BAY1163877 was tested by flow cytometry. The expressions of p-FGFR1/FGFR1 and p-STAT3/STAT3 protein were detected by Western blot. According to the results of qRT-PCR and Western blot, FGFR1 high expression of breast cancer cell line MDA-MB-231 and FGFR1 low expression of breast cancer cell line MCF-7 were selected. BAY1163877 inhibits proliferation of MDA-MB-231 and MCF-7 cells and induces apoptosis of MDA-MB-231 and MCF-7 cells. The results of Western blot showed that the expression of p-FGFR1 and p-STAT3 protein in MDA-MB-231 was reduced after BAY1163877 treatment and the expression in MCF-7 was not significantly changed. BAY1163877 inhibits the proliferation and induces the apoptosis of high FGFR1 expression breast cancer cell line MDA-MB-231, and its mechanism may be related to the decrease of p-FGFR1 and p-STAT3 protein expression. BAY1163877 inhibits the proliferation and induces the apoptosis of MCF-7, but its mechanism still needs the further study.

Publisher

IOP Publishing

Subject

General Medicine

Reference32 articles.

1. Paths of FGFR-driven tumorigenesis;Acevedo;Cell Cycle.,2009

2. Protein tyrosine kinase structure and function;Hubbard,2000

3. Targeting the heparin-binding domain of fibroblast growth factor receptor 1 as a potential cancer therapy;Ling,2015

4. Therapeutics Targeting FGF Signaling Network in Human Diseases;Katoh;Trends Pharmacol Sci.,2016

5. New progress in the research of JAK/STAT signal transduction pathway;He;Journal of New Medicine,2009

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3